Sonelokimab for Biologic-Naive Psoriatic Arthritis

Sonelokimab for Biologic-Naive Psoriatic Arthritis
58%47%36%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 46.0%May 28 • YES 47.8%
MoonLake Immunotherapeutics AG ($MLTX)
No stock close$19.05$17.53$16.00May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • MLTX $16.44May 19 • MLTX $16.37May 20 • MLTX $17.05May 21 • MLTX $18.47May 22 • MLTX $18.19May 26 • MLTX $18.23May 27 • MLTX $18.41May 28 • MLTX $18.68

Will this trial show a positive result on Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Scientific editorial illustration for Psoriatic Arthritis

Psoriatic Arthritis

Psoriatic arthritis is an immune-driven disease causing swollen, painful joints, often in people with psoriasis. ACR50 means at least 50% arthritis improvement, which can mean less pain and easier daily movement.

1General Prevalence: 0.05% to 0.25%2Among People With Psoriasis: 6% to 41%3Typical Timing After Skin Symptoms: 7 to 10 years